(primary solid tumor cohort)
This pipeline maps genes, with mutation or copy number alteration AND this alteration is highly correlated with mRNA expression, to pathways curated in the KEGG and BIOCARTA databases. It identifies pathways significantly enriched with these genes. The pipeline also identifies pathways significantly enriched with marker genes of each expression subtype of cancer.
genes with mutation: identified by the Mutation_Significance pipeline
genes with copy number alteration: identified by the CopyNumber_Gistic2 pipeline
correlation between copy number and mRNA expression: identified by the Correlate_CopyNumber_vs_mRNA pipeline
marker genes and expression subtypes: identified by the mRNAConsensusClustering pipeline
There are 43 genes with significant mutation (Q value <= 0.1) and 195 genes with significant copy number alteration (Q value <= 0.25). The identified marker genes (Q value <= 0.01 or within top 2000) are 2000 for subtype 1, 2000 for subtype 2, 2000 for subtype 3. Pathways significantly enriched with these genes (Q value <= 0.01) are identified :
12 pathways significantly enriched with genes with copy number alteration or mutation.
4 pathways significantly enriched with marker genes of gene expression subtype 1
0 pathways significantly enriched with marker genes of gene expression subtype 2
0 pathways significantly enriched with marker genes of gene expression subtype 3
Pathway | Nof Genes | Nof CNV_Mut | Enrichment | P value | Q value |
---|---|---|---|---|---|
BIOCARTA_RACCYCD_PATHWAY | 26 | 7 | 4.6 | 0 | 0 |
BIOCARTA_TNFR1_PATHWAY | 29 | 6 | 4.2 | 0 | 0.0001 |
BIOCARTA_FAS_PATHWAY | 30 | 5 | 3.9 | 0 | 0.0022 |
BIOCARTA_CDC42RAC_PATHWAY | 16 | 4 | 4.5 | 0 | 0.0022 |
BIOCARTA_PTEN_PATHWAY | 18 | 4 | 4.3 | 0 | 0.0029 |
PIK3CA,PAK1,PIK3R1,TFDP1,RB1,CDKN1B,IKBKB
MAP3K7,CASP8,PAK1,MAP2K4,RB1,RIPK1
MAP3K7,CASP8,PAK1,MAP2K4,RB1
ARPC3,PIK3CA,PAK1,PIK3R1
FOXO3,CDKN1B,PIK3CA,PIK3R1
Pathway | Nof Genes | Nof Marker | Enrichment | P value | Q value |
---|---|---|---|---|---|
KEGG_VASCULAR_SMOOTH_MUSCLE_CONTRACTION | 115 | 24 | 1.3 | 0 | 0.003 |
KEGG_WNT_SIGNALING_PATHWAY | 151 | 29 | 1.1 | 0 | 0.003 |
KEGG_MELANOGENESIS | 102 | 22 | 1.3 | 0 | 0.003 |
KEGG_SYSTEMIC_LUPUS_ERYTHEMATOSUS | 140 | 25 | 1.2 | 0.0001 | 0.0036 |
KEGG_RIBOSOME | 87 | 18 | 1.2 | 0.0003 | 0.014 |
ADCY2,ADCY8,PRKX,PTGIR,PRKACB,ROCK2,MAPK1,PPP1CA,PLA2G2E,PLA2G2F,MYL6,KCNMB2,CACNA1S,AVPR1B,RHOA,GUCY1A3,KCNMA1,PRKCG,PRKCQ,GNAS,GUCY1B3,CALML6,CALML5,RAF1
PRKX,CTNNB1,WNT2,MAP3K7,PRKACB,WNT6,CUL1,ROCK2,RBX1,AXIN1,DVL3,SMAD3,RHOA,PRKCG,SUMO1,CCND3,NKD2,PPP3R2,TCF7L2,PPP2CA,WNT8B,APC,NFATC1,CSNK1A1,FZD1,FZD5,FZD7,TBL1X,TBL1Y
ADCY2,ADCY8,PRKX,CTNNB1,WNT2,CREB3L2,CREB3L1,PRKACB,WNT6,MAPK1,DVL3,PRKCG,GNAS,TCF7L2,CALML6,CALML5,WNT8B,CREB1,FZD1,RAF1,FZD5,FZD7
HIST1H2BO,HIST1H2BM,HIST1H2BK,HIST1H2BL,HIST1H2BG,H2AFY,CD40LG,HLA-DRB5,HLA-DOA,HIST1H4G,HIST1H4H,HIST1H3A,HIST1H3E,HIST3H2A,HIST3H2BB,CD86,CD80,HIST2H2BE,TNF,HIST1H2BD,HIST1H2BE,HIST1H2BH,TRIM21,HIST1H2AH,HIST1H2AK
RPL18,RPL14,RPL13,RPL26L1,FAU,RPS17,RPS13,RPS11,RPL27A,RPL10L,RPS27,RPL30,RPL32,RPL8,RPS21,RPL23A,RPS5,RPL21
Pathway | Nof Genes | Nof Marker | Enrichment | P value | Q value |
---|---|---|---|---|---|
KEGG_PARKINSONS_DISEASE | 130 | 19 | 0.98 | 0.0025 | 0.41 |
KEGG_HUNTINGTONS_DISEASE | 183 | 27 | 0.86 | 0.0013 | 0.41 |
KEGG_NEUROACTIVE_LIGAND_RECEPTOR_INTERACTION | 272 | 36 | 0.61 | 0.0053 | 0.44 |
KEGG_VIRAL_MYOCARDITIS | 73 | 13 | 1.2 | 0.0041 | 0.44 |
BIOCARTA_NKT_PATHWAY | 28 | 7 | 1.5 | 0.008 | 0.44 |
NDUFAB1,COX7B,COX6B1,UBE2L3,ATP5B,UBE2G2,UQCRFS1,NDUFS7,CASP3,CASP9,ATP5H,CYCS,UBB,NDUFB9,ATP5G3,NDUFB1,NDUFA6,SDHD,SLC18A1
NDUFAB1,BDNF,CREB3L3,POLR2J2,DCTN1,COX7B,COX6B1,CREBBP,NFE2L1,ATP5B,PPARG,UQCRFS1,NDUFS7,CASP3,CASP9,DLG4,ATP5H,CYCS,POLR2E,NDUFB9,ATP5G3,POLR2C,NDUFB1,CREB3,NDUFA6,SOD1,SDHD
S1PR1,LTB4R,S1PR5,CRHR1,SSTR1,F2,CHRNB4,CHRNB2,CHRNB1,GPR83,CSH1,MCHR1,TRPV1,EDNRB,NMUR1,RXFP2,GRM1,GRM8,GRM7,GRM6,PARD3,NPY2R,FPR1,GHRHR,CYSLTR1,DRD3,ADORA2A,DRD5,P2RY1,GABRQ,GABRD,GABRA3,P2RX3,CALCRL,PTGER2,PTAFR
CASP3,CASP9,MYH1,CYCS,HLA-A,EIF4G3,SGCG,CD40LG,SGCA,CAV1,RAC3,CD28,MYH11
CCL3,TGFB2,CD4,IFNGR2,CD28,CCR7,CD40LG
Pathway | Nof Genes | Nof Marker | Enrichment | P value | Q value |
---|---|---|---|---|---|
BIOCARTA_PML_PATHWAY | 17 | 8 | 2.4 | 0 | 0.011 |
KEGG_OLFACTORY_TRANSDUCTION | 389 | 57 | 0.72 | 0.0001 | 0.011 |
KEGG_LYSINE_DEGRADATION | 44 | 11 | 1.5 | 0.0009 | 0.097 |
KEGG_ADHERENS_JUNCTION | 75 | 15 | 1.2 | 0.0013 | 0.11 |
KEGG_TGF_BETA_SIGNALING_PATHWAY | 86 | 16 | 1.1 | 0.0024 | 0.16 |
SP100,TNF,CREBBP,SIRT1,DAXX,TNFRSF1A,SUMO1,PRAM1
OR6S1,OR51L1,OR2S2,OR1S1,OR52K2,OR2T2,GUCY2D,OR7E24,OR2W1,OR10AD1,OR5V1,OR4N4,OR4N2,OR6Y1,OR10R2,OR52R1,OR2A12,OR4P4,OR51D1,OR10S1,OR52E6,OR52E8,OR51A4,OR10V1,OR52J3,OR1L6,OR51F2,OR1L3,CALML6,OR8H2,OR1E1,OR4D1,OR13F1,OR7G2,OR13H1,OR4B1,OR8D2,OR8D4,OR10A4,OR52B4,OR2H2,OR2G2,OR13D1,OR4D10,PRKACA,OR4M2,OR5M9,OR5AS1,OR11H4,OR4K1,OR52W1,OR4C15,OR10J5,OR10J1,OR10G2,OR10H1,OR3A3
EHHADH,AASS,PLOD2,PLOD3,AASDH,DLST,EHMT2,DOT1L,ASH1L,SETD7,NSD1
WASF1,VCL,ACTG1,CSNK2A2,RHOA,PTPRM,PTPRF,ACTN3,WASL,PTPRB,PTPN6,TGFBR1,CREBBP,CSNK2B,FYN
FST,RHOA,RBL2,AMH,ACVR1,TNF,DCN,THBS3,TFDP1,TGFBR1,CREBBP,ID2,BMP7,BMP5,BMP8B,BMP8A
Let genes with copy number alteration or mutation be query genes. Let marker genes of specific identified subtypes be query genes. The Enrichment is calculated as:
-
Enrichment = log2 (# of query genes in the pathway/# No of query genes) - log2 (# of genes in the pathway/# of human genes)
The statistical signficance of the pathways that are enriched with genes with copy number alteration or mutation, and the pathways that are enriched with markers genes of specific identified subtypes is measured by P value.
-
P value = Fisher exact P value
The Q value is for adjusting P value for multiple testing. A public available R package is used to calculate the Q value.
This is an experimental feature. The full results of the analysis summarized in this report can be downloaded from the TCGA Data Coordination Center.